The University of Chicago Header Logo

Connection

Ravi Salgia to Immunohistochemistry

This is a "connection" page, showing publications Ravi Salgia has written about Immunohistochemistry.
Connection Strength

0.681
  1. Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
    View in: PubMed
    Score: 0.109
  2. Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers. Cancer Res. 2013 Jan 01; 73(1):184-94.
    View in: PubMed
    Score: 0.081
  3. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010 Jun 11; 285(24):18575-85.
    View in: PubMed
    Score: 0.067
  4. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009 Apr 01; 69(7):3021-31.
    View in: PubMed
    Score: 0.063
  5. FYN is overexpressed in human prostate cancer. BJU Int. 2009 Jan; 103(2):171-7.
    View in: PubMed
    Score: 0.061
  6. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007 Apr 15; 67(8):3529-34.
    View in: PubMed
    Score: 0.055
  7. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007 Apr 01; 13(7):2246-53.
    View in: PubMed
    Score: 0.055
  8. Small-cell cancers, and an unusual reaction to chemotherapy. Case 1. Extrapulmonary small-cell carcinoma arising in the prostate. J Clin Oncol. 2003 Jun 15; 21(12):2437-8.
    View in: PubMed
    Score: 0.042
  9. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001 Feb; 10(1):77-82.
    View in: PubMed
    Score: 0.036
  10. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015 Aug; 5(8):850-9.
    View in: PubMed
    Score: 0.024
  11. EphB4 as a therapeutic target in mesothelioma. BMC Cancer. 2013 May 30; 13:269.
    View in: PubMed
    Score: 0.021
  12. Sphingosine kinase 1 is required for mesothelioma cell proliferation: role of histone acetylation. PLoS One. 2012; 7(9):e45330.
    View in: PubMed
    Score: 0.020
  13. Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res. 2011 Aug 15; 17(16):5257-67.
    View in: PubMed
    Score: 0.018
  14. Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung. Arch Pathol Lab Med. 2010 Nov; 134(11):1702-5.
    View in: PubMed
    Score: 0.018
  15. Reliable and sensitive identification of occult tumor cells using the improved rare event imaging system. Clin Cancer Res. 2004 May 01; 10(9):3020-8.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.